Research at Oslo University Hospital

Cancer researcher and scientist Caroline Nunes-Xavier from the Department of Tumor Biology at the Institute for Cancer Research (OUS) since 2013, receives a prestigious grant from the Spanish Ministry of Science and Innovation, called Contratos Miguel Servet. This is a 5-year funding for her as a young independent researcher, with a potential prolongation of 5 years and a commitment for a permanent position. 

Professor Johanna Olweus from the Department of Cancer Immunology was in 2019 awarded the ERC Consolidator Grant of 20 mill NOK for the immunotherapy project "OUTSOURCE: Outsourcing cancer immunity to healthy donors". 
The OUTSOURCE project has just started, and on that occacsion Olweus has recently been interviewed by the UiO magazine Apollon on how her group of 15 over the next five years will take their research a long step further towards the clinic, how immune cells from healthy individuals can be the new immune cure for cancer, and how this treatment can kill cancer cells without destroying neighbouring cells. 

From 1 January 2021, publicly funded research must be openly available. The Publish and Read agreements make it possible for researchers to publish openly and at the same time completely free of charge. 
The Open Access team at the University of Oslo Library answers the researchers most frequently asked questions.

On this web page you will find an overview over planned and ongoing clinical trials and other research projects at Oslo University Hospital related to COVID-19 and SARS CoV-2 infection. The information has been retrieved from applications to the regional ethics committee, the Norwegian Research Council, other funding sources, or directly from the researchers behind the projects.

Dr. Theo Theodossiou at Department of Radiation Biology, Institute for Cancer Research, received Dr. Ragnar Mørk´s Prize for excellent cancer research in the auditorium of Institute for Cancer Research. Theodossiou received the prize for his research on photosensitizers in selective killing of cancer cells. His innovative research includes luminescence-based photosensitizer activation for killing of brain tumours, and proton-induced photosensitizer activation (proton-dynamic therapy) as a novel way of combining proton therapy with photodynamic therapy.

The Covid-19 pandemic has highlighted the need for rapid and safe testing of agents to treat a high number of SARS-CoV2 infected patients globally. Oslo University Hospital will, together with The Norwegian Institute for Public Health, take part in an ambitious European initiative sponsored by the EU. The project seeks to develop a common platform for clinical trials drawing on expertise from leading hospitals, universities, and research institutions across Europe. 

A European consortium coordinated by Sigrid S. Skånland, researcher at the Department of Cancer Immunology, was awarded the ERA PerMed grant cofunded by the European Commission for their project “CLL-CLUE: Tailoring the targeted treatment of chronic lymphocytic leukemia”.

ERA PerMed is a new ERA-Net Cofund aiming to promote excellence and reinforce the competitiveness of European players in precision medicine. 

Ideally, protein-based biologics could be given transmucosally, rather than intravenously or subcutaneously, but the efficiency of transmucosal drug uptake is poor. In addition, many protein-based biologics hamper from short plasma half-life. 

Scientists at University of Oslo and Oslo University Hospital, in collaboration with international researchers in Italy, Germany and US, have developed a biomedical technology that solves these major challenges.